Category: Epidarex Portfolio News
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”) of its portfolio company Apellis Pharmaceuticals, Inc. (“Apellis”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds…
Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 10,714,000 shares of common…
Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of…
Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve…
Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas ́ Board of Directors Hamburg, 2 November 2017, – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based…
Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and regulatory affairs Hamburg, 26 October 2017, – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase IIb clinical trial…
Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that its complement C3 inhibitor, APL-2, met…